SMITHKLINE BEECHAM IS GOING INTO PBM BUSINESS VIA $2.3 BIL. PURCHASE OF DPS: HMO NICHE OF BUSINESS MAY OFFER CONTROL ADVANTAGE COMPARED TO MEDCO/PAID
SmithKline Beecham is following the Merck vertical integration strategy, but for less than half the investment SB has found a pharmacy benefit manager that has established its position in a separate niche -- with the potential for more control over the drug choices for the covered lives.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth